HUE035774T2 - Biológiai anyagok, különösen oltóanyagok, vákuummal elõsegített tartósítása - Google Patents

Biológiai anyagok, különösen oltóanyagok, vákuummal elõsegített tartósítása Download PDF

Info

Publication number
HUE035774T2
HUE035774T2 HUE12726998A HUE12726998A HUE035774T2 HU E035774 T2 HUE035774 T2 HU E035774T2 HU E12726998 A HUE12726998 A HU E12726998A HU E12726998 A HUE12726998 A HU E12726998A HU E035774 T2 HUE035774 T2 HU E035774T2
Authority
HU
Hungary
Prior art keywords
virus
járás járás
minutes
immunogenic
canine
Prior art date
Application number
HUE12726998A
Other languages
English (en)
Inventor
Noel Genin
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of HUE035774T2 publication Critical patent/HUE035774T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26DRYING
    • F26BDRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13Tumour cells, irrespective of tissue of origin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18051Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (3)

  1. Szabad atärs &amp; igény po ah :<k I, hljás-ás biológiai anyag varifikálásárts, amely tartalmazza a kővetkező lépéseket; folyékony biológiai készítmény Ibrmalázősa, a készttsnéay alávetése a nyomás és hőmérséklet szabályozott, változásainak, ezáltal a kéSzítíóény öéáveSségtartálmétiák mintegy 5 töm«g% alapkő csökkentése* azáltal S biológiai anyag vlirilskhihytg ahol tsz eljárás tartalmazza a következe lépéseket iá: {a> aktiv biológiai összetevők.. stabilizátorok hozzáadása a folyékony készítményhez, amelyek ,>»'K\,sad s.-js MÍnvAvk s ke.»os,\U{ ?sn, OtolOgs«- ibsek kuegóo % »notas-, o-ndokaok tn-tesso vs\ov\"x< s,dt t., bekem< s.esms.evte'îî, v »noMpsot <s t,up,í,zu,í ^ársava, ',go <' Stetem »dukál os ado» -setk n \\ ',,!$* »Ob ,sonn?t s t » a (b) tartőedények töltése ,»> <*»'» * érinti biológiai készinysésiísyel; ;<·) κ tarsöedéöyak betöltése sznbályözett hön-érsékletö könténerbé, ahol » höniérséklet -:50/ és lob közötti,, különösen · IO':'C ős 5<:C közötti es még inkább különösen mintegy 5':C; td) a szabályozóit hOsíscrsáklctó sççgtéder Icvegöcyo-rsásánok csökkentése 15-30 robzr nyomás-eléréséig; te) a (ill lépés során elért nyoniás sonntsftáss 5-20 petéig. különösen iO-IS petetg. ezáltal lehetővé lévé, hogy a léfteék hoo-térsékieie átabiUdilódjap és ez illékony gázok, kÖZtök a karbonátok fslszahadaijarask a biológiai készlttöéitybók ahol sikoetéher hőnoérsékiOlo ézen lépés aktg mintegy á^o-k) vagy mintegy 5ÖG mamd; (í) a kobideór levogőnyemásáhak mintegy 4«? mfeatm vágy mintegy $ tnbartn csőkkootéso 5-2ö percre; (g) az (t) lépés o.yöÍöásáztak lépbtartdsa mintegy 3Ö-00 petrsg, «ms lehetővé teszi a biológiai készítmény töményebbé válását; (is) a konténer hőmémékiététtek emelése negatív hösoézsék létről. pozitív hőmérsékletté tmintegy 30-átk'G) strategy 45-05 percnyi vagy mintegy óé perçntd iddtártásö alatt, és a nyomás áiláado -értéken tartása mintegy !íi-'2íP€, vggy mintegy t.vk) eléréséig) (1) a kontoner iovegöeyossásáttak snimegy 1,5-4 mbarra vagy mintegy 3 otbarra csökkentése, ezáltal a ’,' íkí>' Ό'·, ','Bsa ·,' un a ", "C"<ets<l cl, o ou ,t",ytO'tps ,s m megs n- t. ot rm tegs Oí 0» percig vagy ÓD percig; φ a nyomás további csökkentése mintegy 1),5-4,0 mbarra vagy mintegy I mbarra és állandó nyomás iénetaríása, amíg a habképződés befejeződik: , > ,í \o u to\if’\ ,--0. u'tose "fi<<'s s ’< o pb.r ? >, sgy ! mum, % t,%Ys \o,txr t hőmérséklet mintegy 3Ö“C-o» tartása rt-iotegy 4Ö0-24ÖÖ vagy főbb percig, amíg a mintegy 0,5--15% vagy mintegy 1 -4%,-o;; kívánt- nedveaaéget. eiétjhk; Φ ,s 'ast>'odcn\d, i,'.-sf,amíg a to·.ns.ma sráutc konténerben vonnak, «. coital a utrpikom élj,sots befejezése, ? Λ,- i soots pont \<Y?nm eh-ra.-, abel a-· akti', bmlögsm ,myag smmonogen, pohpepísd, nckk-okl, cto 't η ok- eoo,'· u « ,'lö ,veös<te s,,gs be«."« -et ' tg' -eotív' es-e^ego; »ko o tesőbe »bei esed» ai?mvg 3. A 2> Igéísypobt szerinti -eljárás, alsói az aktív biológiai anyag éió, legyeogtfest \sn«. í s' ..η , xn t s _ 1 e a» ’ , I \ <t>s \ t t u.r uopor to > as n Ibi , - nos s \ ts c s , so 'k I ' s s t s < ' ' ! s sg' >. V x,>ns γ ' s·, ορι \ o\ j o ! s < ; ! <t ' p ,'s < ' > í e ' t K V ! í \ ' i ï'\ - ä s Mod bet >s \ i s fertőző bursitisbetegség vlnna, nyugat-ahusi vin« (WNVs vagy ntacskaiëlék leokőzisvífosa tkeLV). δ. A 2. Igénypont szerinti eljárás, ahol a baktéri um Ävibaeteznnn. ?. Az előző igénypontok bátmelyike szerinti eljárás, ahol a készítmény tartalmaz legalább egy wíiíováaíií.
  2. 8. Az előző igénypontok bármelyike szerinti eljárás, ahol a vkrlflkáU biológiai anyag á^C-ort legalább egy évsg \tabtf,
  3. 9. Az előző igénypontok bármelyike szerinti eljárás, ahol a vimískáh biológiai anyag -200€·οη és •Etre "óh legalább egy évig stobll.
HUE12726998A 2011-08-12 2012-05-31 Biológiai anyagok, különösen oltóanyagok, vákuummal elõsegített tartósítása HUE035774T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161490987P 2011-08-12 2011-08-12

Publications (1)

Publication Number Publication Date
HUE035774T2 true HUE035774T2 (hu) 2018-05-28

Family

ID=46246235

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12726998A HUE035774T2 (hu) 2011-08-12 2012-05-31 Biológiai anyagok, különösen oltóanyagok, vákuummal elõsegített tartósítása

Country Status (13)

Country Link
US (2) US10166188B2 (hu)
EP (1) EP2741740B1 (hu)
JP (1) JP6041361B2 (hu)
CN (1) CN103841963B (hu)
CA (1) CA2844927C (hu)
DK (1) DK2741740T3 (hu)
EA (1) EA031229B1 (hu)
ES (1) ES2626297T3 (hu)
HU (1) HUE035774T2 (hu)
LT (1) LT2741740T (hu)
MX (1) MX350096B (hu)
SI (1) SI2741740T1 (hu)
WO (1) WO2013025274A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191570A1 (en) 2014-06-09 2015-12-17 Upkara, Inc. Capillary assisted vitrification processes and devices
EA201991319A1 (ru) 2016-11-30 2019-11-29 Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
CN107043740A (zh) * 2017-05-10 2017-08-15 浙江美保龙生物技术有限公司 一种mdbk细胞培养液及其制备方法、使用方法
CN107217029A (zh) * 2017-06-08 2017-09-29 浙江美保龙生物技术有限公司 一种pk‑15细胞培养液及其制备方法、使用方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US11287185B1 (en) 2020-09-09 2022-03-29 Stay Fresh Technology, LLC Freeze drying with constant-pressure and constant-temperature phases
CN113046412B (zh) * 2021-03-29 2021-12-14 深圳市麦瑞科林科技有限公司 一种高安全性的非灭活型病毒保存液及制备方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3783098A (en) 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
US3915794A (en) 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
US4000256A (en) 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4431739A (en) 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
EP0386185A1 (fr) 1988-07-29 1990-09-12 IntraCel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5178862A (en) 1989-12-01 1993-01-12 Parhelion Corporation Canine distemper virus vaccine and method of preparation
AT395893B (de) 1990-01-10 1993-03-25 Mayreder Kraus & Co Ing Befestigungsvorrichtung zum verbinden von bauteilen
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
AU650045B2 (en) * 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
ATE197314T1 (de) 1993-02-08 2000-11-15 Bayer Ag Verfahren zum vermehren des das reproduktions- und atemwegs-syndrom verursachenden schweinevirus und dessen verwendung als impfstoff.
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US6485729B1 (en) 1993-09-13 2002-11-26 Protein Sciences Corporation Neuraminidase-supplemented compositions
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
US5869306A (en) 1995-03-17 1999-02-09 Hisamitsu Pharmaceutical Co., Inc. Gene transfer preparation
EP0826063A1 (en) 1995-04-25 1998-03-04 Vical Incorporated Single-vial formulations of dna/lipid complexes
JPH08333277A (ja) 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第xiii因子の安定化された水性液製剤
FR2741806B1 (fr) 1995-11-30 1998-02-20 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus felin de type 1, notamment contre la peritonite infectieuse feline
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US6509146B1 (en) * 1996-05-29 2003-01-21 Universal Preservation Technologies, Inc. Scalable long-term shelf preservation of sensitive biological solutions and suspensions
AU3214597A (en) * 1996-05-29 1998-01-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
DE69740033D1 (de) 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751223B1 (fr) 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
FR2757061B1 (fr) 1996-12-16 1999-03-26 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6290967B1 (en) 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6051238A (en) 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
FR2758986B1 (fr) 1997-01-31 1999-04-30 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6004777A (en) 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
DE69840524D1 (de) 1997-08-13 2009-03-19 Uab Research Foundation Impfung durch topische verwendung genetischer vektoren
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
EP0913177A1 (de) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
WO1999060164A1 (en) 1998-05-15 1999-11-25 Quark Biotech, Inc. Mechanical stress induced genes, expression products therefrom, and uses thereof
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
TR200200477T2 (tr) * 1999-08-24 2002-06-21 Teva Pharmaceutical Industries Limited Bir aşı kompozisyonu ve kullanım yöntemi.
US6872357B1 (en) * 2000-11-22 2005-03-29 Quadrant Drug Delivery Limited Formulation of preservation mixtures containing sensitive biologicals to be stabilized for ambient temperature storage by drying
US20030064000A1 (en) * 2001-09-24 2003-04-03 Wilson Burgess Methods of sterilizing biological mixtures using stabilizer mixtures
AU2003230955A1 (en) * 2002-05-01 2003-11-17 Cryoglass Llc Cryopreservation system for liquid substances
WO2005058356A2 (en) 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
US20060141483A1 (en) 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
EP2377554A1 (en) 2005-07-22 2011-10-19 Amgen, Inc Concentrated protein lyophilates, methods and uses
GB0517688D0 (en) * 2005-08-31 2005-10-05 Cambridge Biostability Ltd Improvements in the stabilisation of biological materials
ES2373238T3 (es) * 2005-09-16 2012-02-01 Merial Ltd. Estabilizadores para vacunas liofilizadas.
KR20080059289A (ko) 2005-10-04 2008-06-26 알크-아벨로 에이/에스 고체 백신 제형
TWI417113B (zh) * 2006-11-07 2013-12-01 Acambis Inc 以凍乾法穩定疫苗
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
US8512679B2 (en) * 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
US11696302B2 (en) 2018-09-10 2023-07-04 Ntt Docomo, Inc. User terminal

Also Published As

Publication number Publication date
WO2013025274A1 (en) 2013-02-21
DK2741740T3 (en) 2017-06-06
JP2014521742A (ja) 2014-08-28
JP6041361B2 (ja) 2016-12-07
EP2741740B1 (en) 2017-05-03
US10166188B2 (en) 2019-01-01
EP2741740A1 (en) 2014-06-18
ES2626297T3 (es) 2017-07-24
US20190070117A1 (en) 2019-03-07
MX2014001626A (es) 2015-03-09
US20130040370A1 (en) 2013-02-14
CN103841963B (zh) 2018-04-24
SI2741740T1 (sl) 2017-08-31
EA201400216A1 (ru) 2014-06-30
US10653627B2 (en) 2020-05-19
CN103841963A (zh) 2014-06-04
CA2844927C (en) 2017-10-31
LT2741740T (lt) 2017-08-10
MX350096B (es) 2017-08-25
CA2844927A1 (en) 2013-02-21
EA031229B1 (ru) 2018-12-28

Similar Documents

Publication Publication Date Title
EP1954308B1 (en) Stabilizers for freeze-dried vaccines
US10653627B2 (en) Method for vacuum-assisted preservation of biologics including vaccines
US8932604B2 (en) Recombinant non-pathogenic marek&#39;s disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
EP3049108B1 (en) Dry formulations of vaccines that are room temperature stable
US20220241421A1 (en) Reduced foaming vaccine compositions
US20180243399A1 (en) Fcv recombinant vaccines and uses thereof